Atopix Therapeutics Limited is a clinical stage biotechnology company, wholly owned by Chiesi Farmaceutici, developing novel treatments for Th2-mediated eosinophilic asthma.
Atopix is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists.
Atopix won a BioMedical Catalyst grant of £1.7M from Innovate UK to advance its lead asset timapiprant through a Phase II study in atopic dermatitis, and helped Imperial College win a £1.3M Biomedical Catalyst award to investigate timapiprant, the company's lead product, for the treatment of asthma triggered by the common cold.
Atopix’s drug programmes target the CRTH2 receptor which plays a pivotal role in the initiation and maintenance of allergic conditions. The company has a pipeline of small molecule drugs, the most advanced of which, timapiprant, is being assessed in three proof-of-concept clinical trials.
Timapiprant has demonstrated efficacy in both asthma and allergic rhinoconjunctivitis. Over 800 patients have been dosed to date and the drug has demonstrated an excellent safety profile.
Atopix drug development programmes are managed by an experienced team with a track-record of progressing drug programmes.